Abstract
Purpose The incidence and risk factors for diabetic retinopathy (DR) in southern China remains unclear. This project aims to explore the onset and progression of DR and their determinants through a prospective cohort in South China.
Methods The Guangzhou Diabetic Eye Study (GDES) recruited patients with type 2 diabetic patients registered in the community health centres in Guangzhou, China. Patients with history of ocular treatment, severe refractive opacity, or other systemic diseases were excluded. Comprehensive examinations were performed including visual acuity, refraction, ocular biometry, fundus imaging, blood and urine tests. The biological samples were collected for further study.
Results A total of 2305 eligible patients were included in the final analysis. In total, 14.58% of the participants had any DR and 4.25% had vision-threatening DR (VTDR), among which 76 (3.30%), 197 (8.55%), 45 (1.95%) and 17 (0.74%) were classified as mild NPDR, moderate NPDR, severe NPDR and PDR, respectively. There were 93 (4.03%) patients of diabetic macular edema (DME). The presence of any DR was independently associated with a longer duration of DM, higher degree of HbA1C, insulin treatment, higher average arterial pressure, higher concentration of serum creatinine, presence of urinary microalbumin, older age, and lower BMI (all P <0.001). For VTDR, 7 factors were significant: older age, a longer duration of DM, higher concentration of HbA1c, use of insulin, lower BMI, higher concentration of serum creatinine, and high albuminuria (all P<0.05). These factors were also independently associated with DME (all P <0.001).
Conclusions The GDES is the first large-scale prospective cohort study of the diabetic population in southern urban China, which will help to identify newer imaging and genetic biomarkers for DR in this population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Natural Science Foundation of China (81570843; 81530028; 81721003), the Guangdong Province Science & Technology Plan (2014B020228002).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Available when appropriate request.
